相关实验视频
Updated: Jun 28, 2025

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
94.4K
用empagliflozin治疗的2型糖尿病患者的代谢控制:一个病例系列
Wilfredo Navarrete1, Pilar Durruty2, Eileen Andrade1
1Consultorio Adosado de Especialidades, Hospital Peñaflor, Peñaflor, Chile.
Medwave
|April 17, 2024
概括
恩帕格利弗洛辛在需要胰岛素的2型糖尿病患者中有效改善了血糖控制. 这种-葡萄糖共运输体2型抑制剂显示出显著的HbA1c降低,具有可管理的安全性.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2DM) 是一种广泛的疾病,与严重的发病率和死亡率有关.
- 不充分的血糖控制仍然是T2DM管理的一个挑战.
- -葡萄糖共运输体2型抑制剂 (SGLT2is) 代表了T2DM的新治疗策略.
研究的目的:
- 评估Empagliflozin在T2DM患者的疗效,在Peñaflor医院需要胰岛素.
- 主要目标:评估empagliflozin对糖化血红蛋白A1c (HbA1c) 的影响.
- 二级目标:分析HbA1c达到7.5%以下的水平,膜过率的变化和尿路白蛋白分泌.
主要方法:
- 对2019年11月至2023年6月用empagliflozin治疗的患者的临床记录的回顾性审查.
- 平均患者随访时间为19个月 (范围:16.3-40个月).
- 统计分析包括配对的t测试或Wilcoxon测试,以在随访期间比较HbA1c值.
主要成果:
- 该研究包括58名患者 (15名男性,43名女性),平均年龄为58.5岁.
- 基线HbA1c为10.3%,在18-24个月的随访后降至8.98%,显著减少1.27% (p=0.002).
- 尿路感染是最常见的不良反应.
结论:
- 恩帕格利弗洛辛在改善胰岛素治疗T2DM患者的血糖控制方面表现出有效性.
- 治疗与HbA1c水平显著降低有关.
- 恩帕格利弗洛辛表现出良好的安全性,副作用最小.
相关概念视频
Diabetes: Management and Pharmacotherapy
275
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
275
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Carbohydrate Metabolism
11.1K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones
195
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
195
Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K

